Digest Network Come funziona
Network
/
Società
Br
Non verificato

Bristol Myers Squibb

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

115 comunicati stampa

Guarda tutti i comunicati
20/01/2026
Tecnica
Tecnologie Varie
Medicina - Varie
Biotecnologia
Farmaceutica
Salute
Information Technology
Oncologia
Mercato del lavoro
Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
12/01/2026
Scienza
Attrezzature medico-sanitarie
Igiene alimentare
Cardiologia
Biotecnologia
Salute
Farmaceutica
Industria
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
02/01/2026
Eventi
Web e Social Network
Biotecnologia
Salute
Scienza
Farmaceutica
Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
19/12/2025
Mercato del lavoro
Industria
Politica Interna
Salute
Farmaceutica
Biotecnologia
Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
18/12/2025
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Salute
Scienza
Farmaceutica
Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
11/12/2025
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
10/12/2025
Titoli e azioni
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Bristol Myers Squibb Announces Dividend Increase
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
08/12/2025
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
05/12/2025
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
03/12/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0